Gene · 10419
Papers3,714
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 3,714
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Therapeutic targeting of chromatin alterations in leukemia and solid tumors. | Int J Cancer | 2026 | 40181550 | PubTator, text mining | PubMed |
| β-1,3-glucan from Euglena gracilis: a promising epidrug targeting epigenetic regulators PRMTs and SIRTs for therapeutic applications in ovarian cancer. | J Biomol Struct Dyn | 2026 | 39535161 | PubTator, text mining | PubMed |
| Exploiting Synthetic Lethality of PRMT5 for Precision Treatment of MTAP-Deficient Glioblastoma. | Int J Transl Med (Basel) | 2025 | 42021873 | PubTator, text mining | PubMed |
| Regulatory links between the circadian clock and stress-induced biomolecular condensates. | NPJ Biol Timing Sleep | 2025 | 41775825 | PubTator, text mining | PubMed |
| PRMT5, regulated by lncRNA ZFAS1/miR-150-5p, promoted androgen-independent prostate cancer migration and invasion. | Arch Med Sci | 2025 | 41684561 | PubTator, text mining | PubMed |
| Replication-associated base excision repair/single-strand break repair regulates PARG inhibitor response via the PRMT1/PRMT5/ATR axis. | NAR Cancer | 2025 | 41480640 | PubTator, text mining | PubMed |
| MTAP Deletion as a Therapeutic Vulnerability in Cancer: From Molecular Mechanism to Clinical Targeting. | Int J Mol Sci | 2025 | 41465382 | PubTator, text mining | PubMed |
| PH20-modified exosomes loaded curcumin inhibit desmoplastic breast cancer by breaking extracellular matrix barrier and normalizing cancer-associated fibroblasts. | Mater Today Bio | 2025 | 41458179 | PubTator, text mining | PubMed |
| MTAP-Null Tumors: A Comprehensive Review on Synthetic Vulnerabilities and Therapeutic Strategies. | Cells | 2025 | 41439984 | PubTator, text mining | PubMed |
| Co-targeting ferroptosis and immune evasion through small molecules in breast cancer. | J Transl Int Med | 2025 | 41438466 | PubTator, text mining | PubMed |
| Histone-related gene WDR77 promotes tumor progression through cell cycle regulation in skin cutaneous melanoma. | Front Immunol | 2025 | 41425556 | PubTator, text mining | PubMed |
| Correction for AbuHammad et al., Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma. | Proc Natl Acad Sci U S A | 2025 | 41417609 | PubTator, text mining | PubMed |
| Correction to: Metadherin-PRMT5 complex enhances the metastasis of hepatocellular carcinoma through the WNT-β-catenin signaling pathway. | Carcinogenesis | 2025 | 41379819 | PubTator, text mining | PubMed |
| A BRET biosensor for measuring uncompetitive engagement of PRMT5 complexes in cells. | Nat Commun | 2025 | 41339334 | PubTator, text mining | PubMed |
| Actionable mutations in pancreatic cancer: where targeted therapies are making a difference. | BMJ Open Gastroenterol | 2025 | 41309265 | PubTator, text mining | PubMed |
| Decreased PPM1B Expression Drives PRMT5-Mediated Histone Modification in Lung Cancer Progression. | Biomolecules | 2025 | 41301499 | PubTator, text mining | PubMed |
| Context-aware gene dependency modeling via graph attention networks for precision oncology. | J Transl Med | 2025 | 41291726 | PubTator, text mining | PubMed |
| Decoding Arginine Dimethylation Isomers via pH-Tuned Reactivity with Methylglyoxal: A Chemical Approach for Functional Proteomics. | J Am Chem Soc | 2025 | 41249876 | PubTator, text mining | PubMed |
| A Further Case for Targeting PRMT5 and the ERK1/2 and PI3K Pathways in CRC. | Int J Mol Sci | 2025 | 41226455 | PubTator, text mining | PubMed |
| Targeting PRMT5 in cancer: Mechanistic insights and clinical progress. | Biomed Pharmacother | 2025 | 41223761 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10419/papers?page=11